Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085280 · ClinicalTrials.gov registry record · NA
Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
A NA study of Stage IV Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- NA
- Development phase
- 129
- Enrollment target
- 1
- Study location
NCT00085280: Completed NA study of Stage IV Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer, sponsored by National Cancer Institute (NCI).
NCT00085280 is a NA study of Stage IV Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 129 participants, below the 684-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00085280, a NA study of Stage IV Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- NA
- Development phase
- 129 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial is studying how well erlotinib works in treating patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG erlotinib hydrochloride
Study Locations (1)
Massachusetts
- Eastern Cooperative Oncology Group - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2004-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00085280
The ClinicalTrials.gov registry entry for NCT00085280 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 684-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (81% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stage IV Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00085280 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00085280 about?
NCT00085280 is a clinical study titled "Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer". This clinical trial is studying how well erlotinib works in treating patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
What is the current status of trial NCT00085280?
This trial is currently completed. It is a NA study. The enrollment target is 129 participants. The study started on 2004-09.
What conditions does trial NCT00085280 study?
This clinical trial studies the following conditions: Stage IV Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT00085280?
The interventions under investigation include: laboratory biomarker analysis (OTHER), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00085280?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00085280 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Patient-centered, Optimal Integration of Survivorship and Palliative Care
RECRUITING · NA
-
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
RECRUITING · NA
-
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
RECRUITING · NA
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
ACTIVE NOT RECRUITING · Phase 1
-
Ruxolitinib for Cancer Cachexia
ACTIVE NOT RECRUITING · Early Phase 1
Explore more on PlainTrial
Stage IV Non-small Cell Lung Cancer
All registered trials for this condition
Stage IIIB Non-small Cell Lung Cancer
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.